Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* primary diagnosis of infiltrating breast cancer~* HR positivity (ER ≥ 10% and/or PgR ≥10%) and HER2 positivity (IHC 3+ or FISH/CISH amplification), as assessed by local laboratory.~* Stage II-IIIA~* age \>18 yrs~* ECOG Performance Status 0-1~* Postmenopausal status, defined by at least one of the following:~  60 years of age; \< 60 years of age and amenorrheic for \>/=12 months prior to day 1 \< 60 years of age, without a uterus, and luteinizing hormone (LH) and follicle stimulating hormone (FSH) values within postmenopausal range Prior bilateral oophorectomy Prior radiation castration with amenorrhea for at least 6 months~* Cardiac ejection fraction within the institutional range of normal (as measured by echocardiogram or MUGA scan).~* Normal organ and marrow function as defined below:~(leukocytes \>=3000/mcL; absolute neutrophil count \>=1,500/mcL; platelets \>=100,000/mcL; total bilirubin within 1.25 x normal institutional limits (with the exception of Gilbert's syndrome); AST (SGOT)/ALT(SGPT) within 1.25 x institutional upper limit of normal creatinine within normal institutional limits~* Availability of tumor tissue suitable for biological and molecular examination before starting primary treatment~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Stage IIIB, IIIC, and inflammatory breast cancer~* Stage IV breast cancer~* Prior treatment with chemotherapy, endocrine therapy or radiotherapy. Prior treatment with HER2 targeting therapies~* LVEF below the ULN~* Uncontrolled hypertension (systolic \>150 mm Hg and/or diastolic \>100 mm Hg) or clinically significant (i.e. active) cardiovascular disease: cerebrovascular accident (CVA)/stroke or myocardial infarction within 6 months prior to first study medication, unstable angina, congestive heart failure (CHF) of New York Heart Association (NYHA) grade II or higher, or serious cardiac arrhythmia requiring medication.~* Received any investigational treatment within 4 weeks of study start.~* Subjects with known infection with HIV, HBV, HCV~* Known hypersensitivity to any of the study drugs or excipients.~* Dyspnoea at rest or other disease requiring continuous oxygen therapy.~* Psychiatric illness/social situations that would limit compliance with study requirements~* Subjects assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pertuzumab, Trastuzumab, Letrozole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).